Moreover, the 36-month beta value for SNSE is 0.12. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SNSE is 16.54M and currently, short sellers hold a 1.18% of that float. On November 26, 2024, SNSE’s average trading volume was 380.99K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SNSE) stock’s latest price update
The stock of Sensei Biotherapeutics Inc (NASDAQ: SNSE) has increased by 15.14 when compared to last closing price of 0.52.Despite this, the company has seen a gain of 19.52% in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that – SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 – – Organizational restructuring to focus resources on advancing the clinical development of SNS-101 – – Cash runway extended into the second quarter of 2026 – BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. “The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 across dose levels and patients with primary and acquired resistance to PD-1 inhibitors.
SNSE’s Market Performance
SNSE’s stock has risen by 19.52% in the past week, with a monthly rise of 7.16% and a quarterly drop of -2.93%. The volatility ratio for the week is 15.09% while the volatility levels for the last 30 days are 12.53% for Sensei Biotherapeutics Inc The simple moving average for the past 20 days is 15.57% for SNSE’s stock, with a -22.93% simple moving average for the past 200 days.
Analysts’ Opinion of SNSE
Many brokerage firms have already submitted their reports for SNSE stocks, with Stephens repeating the rating for SNSE by listing it as a “Overweight.” The predicted price for SNSE in the upcoming period, according to Stephens is $5 based on the research report published on May 14, 2024 of the current year 2024.
Berenberg, on the other hand, stated in their research note that they expect to see SNSE reach a price target of $12. The rating they have provided for SNSE stocks is “Hold” according to the report published on July 01st, 2021.
Oppenheimer gave a rating of “Perform” to SNSE, setting the target price at $14 in the report published on June 29th of the previous year.
SNSE Trading at 15.71% from the 50-Day Moving Average
After a stumble in the market that brought SNSE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.07% of loss for the given period.
Volatility was left at 12.53%, however, over the last 30 days, the volatility rate increased by 15.09%, as shares surge +1.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.26% upper at present.
During the last 5 trading sessions, SNSE rose by +19.52%, which changed the moving average for the period of 200-days by -29.25% in comparison to the 20-day moving average, which settled at $0.5191. In addition, Sensei Biotherapeutics Inc saw -13.29% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SNSE
Current profitability levels for the company are sitting at:
- -11.41 for the present operating margin
- 0.86 for the gross margin
The net margin for Sensei Biotherapeutics Inc stands at -10.47. The total capital return value is set at -0.68. Equity return is now at value -51.04, with -44.18 for asset returns.
Currently, EBITDA for the company is -33.39 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.84.
Conclusion
To wrap up, the performance of Sensei Biotherapeutics Inc (SNSE) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
